<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04626687</url>
  </required_header>
  <id_info>
    <org_study_id>ACOART paclitaxel SVD</org_study_id>
    <nct_id>NCT04626687</nct_id>
  </id_info>
  <brief_title>ACOART Paclitaxel SVD:Paclitaxel Coated Coronary Balloon Catheter in Treatment of Coronary Small Vessel Diseases</brief_title>
  <official_title>Paclitaxel Coated Coronary Balloon Catheter in Treatment of Coronary Small Vessel Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acotec Scientific Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Tongji Hospital, Tongji University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Acotec Scientific Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the trial is to determine whether DCB made by Acotec Scientific is not&#xD;
      inferior to RESTORE DEB made by CARDIONOVUM GmbH in treatment of small vessel coronary&#xD;
      disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multi-center, randomized-controlled clinical trial to verify the&#xD;
      efficacy and safety of DCB made by Acotec Scientific versus RESTORE DEB in treatment of small&#xD;
      vessel coronary disease. And the primary endpoint is angiographic restenosis at 9 months&#xD;
      post-procedure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 6, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Angiographic percent diameter stenosis</measure>
    <time_frame>at 9 months post-procedure</time_frame>
    <description>(1-Segmental minimum lumen diameter [MLD]/ segmental reference vessel diameter [RVD]) ×100%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute success</measure>
    <time_frame>in the procedure</time_frame>
    <description>Including instrument success rate, lesion success rate and surgical success rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of target lesion failure</measure>
    <time_frame>within 12 months post-procedure</time_frame>
    <description>A composite of cardiac death, target-vessel related myocardial infarction, and ischemia-driven target lesion revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diameter stenosis in-device</measure>
    <time_frame>at 9 months post-procedure</time_frame>
    <description>(1-the minimum cavity diameter of the device [MLD] / the reference vessel diameter of the device [RVD]) ×100%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late lumen loss</measure>
    <time_frame>at 9 months post-procedure</time_frame>
    <description>Loss of late lumen in the segment and device</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">230</enrollment>
  <condition>Coronary Disease</condition>
  <arm_group>
    <arm_group_label>test DCB group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>use the DCB made by Acotec Scientific</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RESTORE DCB group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>use the DCB made by CARDIONOVUM GmbH</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>test DCB</intervention_name>
    <description>use paclitaxel coated coronary balloon catheters to treat SVD</description>
    <arm_group_label>test DCB group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RESTORE DCB</intervention_name>
    <description>use paclitaxel coated coronary balloon catheters(RESTORE DCB) with NMPA approval indication for treating SVD</description>
    <arm_group_label>RESTORE DCB group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 to 80 years of age&#xD;
&#xD;
          -  Subjects with symptomatic coronary artery disease with stable and unstable angina&#xD;
             pectoris or secondary evaluation of stenosis after acute myocardial infarction (MI)&#xD;
             and asymptomatic subjects with coronary atherosclerotic stenosis causing myocardial&#xD;
             ischemia determined by the investigator&#xD;
&#xD;
          -  Subjects with single, de novo lesion with stenosis of more than 70% (or more than 50%&#xD;
             combined with symptoms of ischemia) in a vessel with visually estimated reference&#xD;
             vessel diameter (RVD) ≥ 2.00 mm and ≤ 2.75 mm, and ≤ 26 mm in length.&#xD;
&#xD;
          -  Subject must agree to clinical follow-up at 1, 6, 9, 12 months, and angiographic&#xD;
             follow-up at 9 months.&#xD;
&#xD;
          -  Subject can understand the study objectives psychologically and linguistically and&#xD;
             shows sufficient compliance to the study protocol. Subjects express acceptance of the&#xD;
             risks and benefits described in the informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  AMI within 1 week.&#xD;
&#xD;
          -  Subject has congestive heart failure or NYHA IV.&#xD;
&#xD;
          -  Subject with LVEF &lt; 35%.&#xD;
&#xD;
          -  Subject has undergone heart transplantation.&#xD;
&#xD;
          -  Subject has cardiac arrhythmias, such as high-risk ventricular premature beat and/or&#xD;
             ventricular tachycardia.&#xD;
&#xD;
          -  Subject suffered stroke, gastrointestinal bleeding or active ulcer within the past 6&#xD;
             months, or with conditions associated with high risk of bleeding.&#xD;
&#xD;
          -  Subject with a history of leukopenia (white blood cell count of &lt; 3×109/L for &gt;3&#xD;
             days), neutropenia (ANC&lt;1000/mm3 for &gt;3 days) or thrombocytopenia (platelet&#xD;
             &lt;100,000/mm3).&#xD;
&#xD;
          -  Known renal insufficiency (eGFR&lt;30 ml/min).&#xD;
&#xD;
          -  Subject who is forbidden to use anticoagulation agents or anti-platelet drugs, and&#xD;
             tolerate Aspirin or Clopidogrel.&#xD;
&#xD;
          -  Life expectancy less than 12 months, or subjects who cannot complete 12-month&#xD;
             follow-up.&#xD;
&#xD;
          -  Pregnant or nursing subjects and those who plan pregnancy in the period up to 1 year&#xD;
             following index procedure.&#xD;
&#xD;
          -  Subject is currently participating in another investigational drug or device study&#xD;
             that has not yet completed its primary endpoint.&#xD;
&#xD;
          -  Subject unsuitable for study according to the investigator due to the investigator due&#xD;
             to other reasons related to diseases.&#xD;
&#xD;
          -  Angiography exclusions:Target lesion: Total occlusion lesion (TIMI 0), heavy calcified&#xD;
             lesion that cannot be successfully dilated, bifurcation lesion (side branch ≥ 2.0 mm&#xD;
             in diameter), restenosis lesion, thrombotic lesion, or left main disease;Non-target&#xD;
             lesion: More than 2 non-target lesions or non-target lesion cannot be successfully&#xD;
             treated.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xuebo Liu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Tongji Hospital, Tongji University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xuebo Liu, MD</last_name>
    <phone>13801926702</phone>
    <email>lxb70@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Tongji Hospital, Tongji University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xuebo Liu, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>November 4, 2020</study_first_submitted>
  <study_first_submitted_qc>November 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 12, 2020</study_first_posted>
  <last_update_submitted>June 17, 2021</last_update_submitted>
  <last_update_submitted_qc>June 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>coronary small vessel diseases</keyword>
  <keyword>DCB</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

